| Antibody-based therapy of leukaemia. | |
| | |
MedLine Citation:
|
PMID: 19788782 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Over the past decade, monoclonal antibodies have dramatically impacted the treatment of haematological malignancies, as evidenced by the effect of rituximab on the response rate and survival of patients with follicular and diffuse large B cell non-Hodgkin's lymphoma. Currently, only two monoclonal antibodies - the anti-CD33 immunotoxin gemtuzumab ozogamicin and the CD52-directed antibody alemtuzumab - are approved for treatment of relapsed acute myeloid leukaemia in older patients and B cell chronic lymphocytic leukaemia, respectively. Although not approved for such treatment, alemtuzumab is also active against T cell prolymphocytic leukaemia, cutaneous T cell lymphoma and Sézary syndrome, and adult T cell leukaemia and lymphoma. In addition, rituximab has demonstrated activity against B cell chronic lymphocytic and hairy cell leukaemia. Monoclonal antibodies targeting CD4, CD19, CD20, CD22, CD23, CD25, CD45, CD66 and CD122 are now being studied in the clinic for the treatment of leukaemia. Here, we discuss how these new antibodies have been engineered to reduce immunogenicity and improve antibody targeting and binding. Improved interactions with Fc receptors on immune effector cells can enhance destruction of target cells through antibody-dependent cellular cytotoxicity and complement-mediated cell lysis. The antibodies can also be armed with cellular toxins or radionuclides to enhance the destruction of leukaemia cells. |
| | |
Authors:
|
John C Morris; Thomas A Waldmann |
Publication Detail:
|
Type: Journal Article; Research Support, N.I.H., Intramural; Review Date: 2009-09-30 |
Journal Detail:
|
Title: Expert reviews in molecular medicine Volume: 11 ISSN: 1462-3994 ISO Abbreviation: Expert Rev Mol Med Publication Date: 2009 |
Date Detail:
|
Created Date: 2009-09-30 Completed Date: 2009-11-24 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 100939725 Medline TA: Expert Rev Mol Med Country: England |
Other Details:
|
Languages: eng Pagination: e29 Citation Subset: IM |
Affiliation:
|
Metabolism Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892-1457, USA. jmorris@mail.nih.gov |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Antibodies, Monoclonal / therapeutic use* Antigens, CD / immunology Clinical Trials as Topic Hematologic Neoplasms / immunology, therapy* Humans Immunologic Factors / therapeutic use* Immunotoxins / therapeutic use* Leukemia / immunology, therapy* |
| Chemical | |
Reg. No./Substance:
|
0/Antibodies, Monoclonal; 0/Antigens, CD; 0/Immunologic Factors; 0/Immunotoxins |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Regression of Left Ventricular Dilation After Percutaneous Closure of a Large Intralobar Pulmonary S...
Next Document: Prevalence of and risk factors for methicillin-resistant Staphylococcus aureus skin and soft tissue ...